Mackenzie Financial’s Haemonetics HAE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-3,021
Closed -$244K 1559
2025
Q4
$244K Buy
+3,021
New +$203K ﹤0.01% 1461
2025
Q3
Sell
-3,165
Closed -$236K 1760
2025
Q2
$236K Hold
3,165
﹤0.01% 1488
2025
Q1
$201K Hold
3,165
﹤0.01% 1522
2024
Q4
$247K Hold
3,165
﹤0.01% 1464
2024
Q3
$254K Hold
3,165
﹤0.01% 1264
2024
Q2
$262K Hold
3,165
﹤0.01% 1224
2024
Q1
$270K Hold
3,165
﹤0.01% 1218
2023
Q4
$271K Hold
3,165
﹤0.01% 1196
2023
Q3
$276K Hold
3,165
﹤0.01% 1166
2023
Q2
$265K Sell
3,165
-9,032
-74% -$764K ﹤0.01% 1213
2023
Q1
$1.01M Buy
12,197
+2,687
+28% +$218K ﹤0.01% 856
2022
Q4
$748K Buy
9,510
+6,178
+185% +$497K ﹤0.01% 821
2022
Q3
$247K Sell
3,332
-166
-5% -$11.9K ﹤0.01% 1162
2022
Q2
$228K Buy
+3,498
New +$207K ﹤0.01% 1225
2021
Q4
Sell
-2,959
Closed -$209K 1460
2021
Q3
$209K Buy
+2,959
New +$187K ﹤0.01% 1307
2020
Q3
Sell
-5,922
Closed -$530K 1013
2020
Q2
$530K Sell
5,922
-340
-5% -$34.3K ﹤0.01% 783
2020
Q1
$624K Buy
6,262
+762
+14% +$82.6K ﹤0.01% 768
2019
Q4
$632K Sell
5,500
-18,293
-77% -$2.21M ﹤0.01% 819
2019
Q3
$3M Buy
23,793
+443
+2% +$56.2K 0.01% 541
2019
Q2
$2.81M Sell
23,350
-91,125
-80% -$8.97M 0.01% 561
2019
Q1
$10M Sell
114,475
-81,750
-42% -$7.43M 0.02% 371
2018
Q4
$19.6M Buy
196,225
+21,175
+12% +$2.22M 0.05% 251
2018
Q3
$20.1M Buy
175,050
+51,620
+42% +$5.34M 0.05% 237
2018
Q2
$11.1M Buy
+123,430
New +$10.4M 0.03% 303
2013
Q3
Sell
-51,400
Closed -$2.13M 637
2013
Q2
$2.13M Buy
+51,400
New +$2.08M 0.01% 382

Other funds holding HAE

Mackenzie Financial's HAE Position: Q1 2026 in Review

Mackenzie Financial sold out of Haemonetics (HAE) in Q1 2026, closing a stake of 3,021 shares — an estimated $244K sold.

Mackenzie Financial first reported a position in HAE in Q2 2013 and held it in 25 quarters. The position peaked at $20.1M in Q3 2018. 324 funds tracked by Wall St. Rank hold HAE as of Q1 2026.

  • Mackenzie Financial reported no remaining Haemonetics position as of Q1 2026 after selling out during the quarter.
  • Mackenzie Financial sold 3,021 Haemonetics shares in Q1 2026, an estimated $244K.
  • Mackenzie Financial first reported a position in Haemonetics in Q2 2013 and held it in 25 quarters.
  • Mackenzie Financial's Haemonetics position peaked at $20.1M in Q3 2018.
  • 324 funds tracked by Wall St. Rank held Haemonetics as of Q1 2026.

Based on Mackenzie Financial's 13F filing for Q1 2026, filed 13 May 2026.